Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Cash from Financing Activities (2016 - 2025)

Integra Lifesciences Holdings' Cash from Financing Activities history spans 16 years, with the latest figure at $24.3 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 440.45% year-over-year to $24.3 million; the TTM value through Dec 2025 reached $28.3 million, down 88.09%, while the annual FY2025 figure was $28.3 million, 88.09% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $24.3 million at Integra Lifesciences Holdings, up from -$10.2 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $358.7 million in Q1 2024 and bottomed at -$162.7 million in Q1 2023.
  • The 5-year median for Cash from Financing Activities is -$10.5 million (2023), against an average of -$15.7 million.
  • The largest annual shift saw Cash from Financing Activities tumbled 18852.21% in 2022 before it surged 440.45% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $521000.0 in 2021, then crashed by 18852.21% to -$97.7 million in 2022, then soared by 92.95% to -$6.9 million in 2023, then fell by 3.77% to -$7.2 million in 2024, then soared by 440.45% to $24.3 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Cash from Financing Activities are $24.3 million (Q4 2025), -$10.2 million (Q3 2025), and -$21.1 million (Q2 2025).